Cabergoline(FCE21336,一种新型长效多巴胺能麦角衍生物)能降低大鼠、正常人、各种高催乳素(PRL)血症的 PRL 水平。但小剂量 Cabergoline不能降低肢端肥大症患者生长激素(GH)水平。为了研究其原因,作者观察了多巴胺敏感的肢端肥大症患者单次及多次口服大剂量 Cabergoline 后血 PRL 和GH 的改变及持续时间。活动期肢端肥大症8例 CT 扫描均提示有垂体微腺瘤。除1例服用甲状腺素外,治疗前一月停用所有药物。单剂试验者均于上午8时空腹服药。先予溴隐 Cabergoline (FCE21336, a novel long-acting dopamine ergot derivative) reduces PRL levels in rats, normal subjects and various hyperprolactine (PRL) hyperlipidemias. However, low doses of Cabergoline do not reduce GH levels in patients with acromegaly. In order to investigate its causes, the authors observed changes and durations of blood PRL and GH after single and multiple oral doses of Cabergoline in patients with dopaminergic acromegaly. Acromegaly active hypertrophy in 8 cases of CT scan tips are pituitary adenoma. Except for 1 case of thyroxine, all drugs were discontinued the previous month. A single dose of test were taken at 8 am on an empty stomach. First bromine hidden